Literature DB >> 218731

Modulation of plasminogen activator synthesis in chick embryo fibroblasts by cyclic nucleotides and phorobol myristate acetate.

E L Wilson, E Reich.   

Abstract

To explore the interaction of tumor promoters and sarcoma virus transformation with cellular regulatory mechanisms, we have studied induction of plasminogen activator synthesis by these agents in a background of changing cyclic nucleotide concentrations. We have confirmed the original report of Wigler and Weinstein (Nature, 259: 232, 1976) that phorbol-12-myristate-13-acetate (PMA), a potent tumor promoter, induces high levels of plasminogen activator production by chick embryo fibroblasts. Sarcoma virus transformation sensitizes the fibroblasts by lowering the threshold concentration for response to the action of PMA, and the effects of transformation and PMA on plasminogen activator synthesis are synergistic rather than additive. The plasminogen activators produced in the PMA-, virus-induced, or synergistically stimulated cultures are indistinguishable. Enzyme production in all three conditions is strongly but reversibly inhibited when cyclic nucleotide levels are raised by exposure to cyclic adenosine-3':5'-monophosphate or cholera toxin. A substantial fraction of the morphological effect that accompanies transformation is not affected by concentrations of cyclic nucleotides that suppress plasminogen activator production, and the two phenomena are therefore at least partially independent expressions of transformation in this system.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 218731

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Microinjected Xenopus oocytes synthesize active human plasminogen activator.

Authors:  R Miskin; H Soreq
Journal:  Nucleic Acids Res       Date:  1981-07-24       Impact factor: 16.971

2.  Paradoxical effects of glucocorticoids on regulation of plasminogen activator activity of rat hepatoma cells.

Authors:  P A Barouski-Miller; T D Gelehrter
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

3.  Tumor promoters increase the synthesis of a 32,000-dalton protein in BALB/c 3T3 cells.

Authors:  T Hiwasa; S Fujimura; S Sakiyama
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

4.  Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases.

Authors:  S M Bell; D C Connolly; N J Maihle; J L Degen
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

5.  Plasminogen activator induction and platelet aggregation by phorbol and some of its derivatives: correlation with skin irritancy and tumor-promoting activity.

Authors:  P J Brynes; R Schmidt; E Hecker
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

6.  Opposite and independent actions of cyclic AMP and transforming growth factor beta in the regulation of type 1 plasminogen activator inhibitor expression.

Authors:  F W Thalacker; M Nilsen-Hamilton
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

7.  Plasminogen activator: analysis of enzyme induction by ultraviolet irradiation mapping.

Authors:  R Miskin; E Reich; K Dixon
Journal:  Mol Cell Biol       Date:  1981-10       Impact factor: 4.272

8.  Hormonal regulation of plasminogen activator in rat hepatoma cells.

Authors:  T D Gelehrter; P A Barouski-Miller; P L Coleman; B J Cwikel
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

9.  Tumor production in the nude mouse, fibrinolytic activity and cross-reactivity with antimelanoma sera of various human tumor cell lines.

Authors:  J Brüggen; J Fogh; C Sorg
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

10.  Determination of tissue-type plasminogen-activator mRNA in human and non-human cell lines by dot-blot hybridization.

Authors:  G Opdenakker; A Billiau; G Volckaert; P de Somer
Journal:  Biochem J       Date:  1985-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.